A
Andreas Makris
Researcher at Northwood University
Publications - 130
Citations - 6167
Andreas Makris is an academic researcher from Northwood University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 39, co-authored 122 publications receiving 5515 citations. Previous affiliations of Andreas Makris include The Breast Cancer Research Foundation & University of Hertfordshire.
Papers
More filters
Journal ArticleDOI
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
Manfred Kaufmann,Gabriel N. Hortobagyi,Aron Goldhirsch,Suzy Scholl,Andreas Makris,Pinuccia Valagussa,Jens-Uwe Blohmer,Wolfgang Eiermann,Raimund Jackesz,Walter Jonat,Annette Lebeau,Sibylle Loibl,William B. Miller,Sigfried Seeber,Vladimir Semiglazov,Roy E. Smith,Rainer Souchon,Vered Stearns,Michael Untch,Gunter von Minckwitz +19 more
TL;DR: A second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update recommendations regarding neoadjuvant treatment for operable disease and data published to date were reviewed critically and indications were newly defined.
Journal ArticleDOI
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
Manfred Kaufmann,G. von Minckwitz,Harry D. Bear,Aman U. Buzdar,Paul McGale,H. Bonnefoi,Marco Colleoni,Carsten Denkert,Wolfgang Eiermann,R. Jackesz,Andreas Makris,William R. Miller,J-Y Pierga,Vladimir Semiglazov,Andreas Schneeweiss,Rainer Souchon,Vered Stearns,Michael Untch,Sibylle Loibl +18 more
TL;DR: A third international panel of representatives of a number of breast cancer clinical research groups was convened in September 2006 to update recommendations regarding neoadjuvant treatment for operable disease, and indications for neoadJuvant treatment were newly defined.
Journal ArticleDOI
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.
T. J. Powles,Tamas Hickish,Andreas Makris,Sue Ashley,Mary O'Brien,V. A. Tidy,S Casey,A. G. Nash,N. Sacks,David O. Cosgrove +9 more
TL;DR: This trial is the first to include small primary cancers and to show, in the context of a randomized trial, a reduction in the requirement for mastectomy, and such neoadjuvant treatment cannot be recommended outside of a clinical trial.
Journal ArticleDOI
Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Mei-Lin Ah-See,Andreas Makris,N. Jane Taylor,Mark Harrison,P I Richman,RJ Burcombe,J. James Stirling,James A. d’Arcy,David J. Collins,M. Pittam,D Ravichandran,Anwar R. Padhani +11 more
TL;DR: Changes in breast tumor microvessel functionality as depicted by DCE-MRI early on after starting anthracycline-based neoadjuvant chemotherapy can predict final clinical and pathologic response.
Journal ArticleDOI
Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: Initial clinical results
Anwar R. Padhani,Carmel Hayes,L. Assersohn,Trevor J. Powles,Andreas Makris,John Suckling,Martin O. Leach,Janet E. Husband +7 more
TL;DR: Reductions in MR imaging-determined size of the primary tumor best predict clinicopathologic response of breast cancer after one cycle of neoadjuvant chemotherapy.